Dr. Haiyong Wang 王海永
Chief Physician
Department of Respiratory Medicine, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Lung cancer, including non-small cell and small cell lung cancer, lung nodules, and lung masses.
Dr. Wang holds a medical doctorate from Fudan University and completed postdoctoral training in oncology at Shandong University. A visiting scholar at the University of Macau, Dr. Wang is a Taishan Scholar Young Expert. Research includes over 50 papers in journals such as J Thorac Oncol and presentations at WCLC and ESMO. Dr. Wang serves as Sub-Investigator in multiple clinical drug trials.
Professional roles
- Chair, Palliative Care Branch, Shandong Medical Association
- Council Member, Youth Council, Shandong Anti-Cancer Association
- Chair, Lung Cancer Youth Committee, Shandong Anti-Cancer Association
- Chair, Small Cell Lung Cancer Youth Committee, Shandong Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Haiyong). Papers usually list the name as Haiyong Wang or Wang H.
Selected publications
116 papers on PubMed matched by name and affiliation; 71 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Transl Immunology, 2026 (first author): Spatial and maturational characterisation of tertiary lymphoid structures predicts immunotherapy response in extensive-stage small cell lung cancer. PubMed 42903730
- MedComm (2020), 2026 (senior author): Dynamic Granulocyte Turnover Inferred From cfDNA Methylation Predicts Immunotherapy Benefit in Liver-Metastatic Small Cell Lung Cancer: A Prospective Biomarker Study. PubMed 42609700
- J Thorac Dis, 2026 (first author): Clarifying the role of flumonertinib rechallenge in EGFR-mutated non-small cell lung cancer. PubMed 42306760
- J Thorac Dis, 2026 (first author): Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study. PubMed 41660441
- Adv Biol (Weinh), 2026 (first author): Feiwei Mixture Exerts Antitumor Activity Against Non-Small Cell Lung Cancer via Regulating NR1D1-Mediated Immune Cell Infiltration. PubMed 41725319
- Biochim Biophys Acta Rev Cancer, 2025 (first author): The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application. PubMed 40915429
- Adv Sci (Weinh), 2025 (senior author): The LDH-H3K18La-Nur77 Axis Potentiates Immune Escape in Small Cell Lung Cancer. PubMed 40552757
- Crit Rev Oncol Hematol, 2025 (senior author): The emerging landscape and future perspective of SCLC transformation: From molecular mechanisms to therapeutic strategies. PubMed 39805410
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion